AEON
AEON Biopharma, Inc.
$0.6700
+0.75%
$17.6M
No data for this timeframe.
Vol
Market Cap$17.6M
Cap SizeNano Cap
Inst. Holders8 funds
Inst. Value$107.5K
Inst. Activity0 buys / 1 sells
SEC Reports3
Press Releases2
Recent Activity
Jun 4, 2026
other
AEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache Society
<p align="justify">IRVINE, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON”
May 14, 2026
SEC
AEON Biopharma reported Q1 2026 results with a net loss of $11.8M ($-0.29/share), compared to net income of $9.1M ($2.28
8-K — Impact 5/10
Apr 29, 2026
SEC
AEON Biopharma filed a DEFA14A notice of availability of proxy materials for its 2026 Annual Meeting on June 17, 2026. T
DEFA14A — Impact 2/10
Apr 3, 2026
SEC
AEON Biopharma received an additional delisting notice from NYSE American due to a stockholders' deficit of approximatel
8-K — Impact 8/10
Apr 2, 2026
Insider
Bencich John was granted 754,717 shares
CHIEF FINANCIAL OFFICER
Mar 4, 2026
Insider
Oh Chad was granted 1,316,872 shares
CHIEF MEDICAL OFFICER
Mar 4, 2026
Insider
Wilson Alexander Blair was granted 1,316,872 shares
CLO, CSO, and Corp Secretary
Inst.
UBS Group AG — NEAR_EXIT
1,192 shares ($964.00)
Price Targets
Historical data — last covering-analyst action Oct 2025. No current recommendation available.
$6.70 (Oct 2025)
Current $0.6704
Low $5.00
Median $6.70
High $8.40
2 analysts
$5.00
$8.40
Analyst Ratings
2Strong Buy
5Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 8, 2025 | Aegis Capital | REITERATE | Buy → Buy |
| Oct 1, 2024 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Aug 14, 2024 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Jul 10, 2024 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| May 30, 2024 | HC Wainwright & Co. | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.33 ▲ +49.2% | $-0.33 — $-0.33 | 45% YoY | 1 |
| Next Q | $-0.27 ▲ +50.0% | $-0.27 — $-0.27 | 31% YoY | 1 |
| Current FY | $-1.05 ▲ +46.4% | $-1.05 — $-1.05 | 73% YoY | 1 |
Latest Reports
NEUTRAL
8-K
5/10
AEON Biopharma reported Q1 2026 results with a net loss of $11.8M ($-0.29/share), compared to net income of $9.1M ($2.28
May 14, 2026
NEUTRAL
DEFA14A
2/10
AEON Biopharma filed a DEFA14A notice of availability of proxy materials for its 2026 Annual Meeting on June 17, 2026. T
Apr 29, 2026
BEARISH
Press
7/10
AEON Biopharma received a notice from NYSE American that it is now non-compliant with an additional listing standard due
Apr 3, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $89.2K | — |
| VANGUARD FIDUCIARY TRUST CO | $14.5K | — |
| BlackRock, Inc. | $2.8K | — |
| CITIGROUP INC | $731.00 | — |
| MORGAN STANLEY | $148.00 | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 2, 2026 | Bencich John | A | $0.00 |
| Mar 4, 2026 | Oh Chad | A | $0.00 |
| Mar 4, 2026 | Wilson Alexander | A | $0.00 |
| Mar 4, 2026 | Sy Jennifer | A | $0.00 |
| Feb 17, 2026 | Wilson Alexander | A | $0.00 |
8 institutional holders with $107.5K total value (109,150 shares) as of 2026-Q1. Top holders: VANGUARD, VANGUARD, BlackRock,.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 90,529 | $89.2K | 82.9% | — |
| 2 | VANGUARD FIDUCIARY TRUST CO | 14,702 | $14.5K | 13.5% | — |
| 3 | BlackRock, Inc. | 2,834 | $2.8K | 2.6% | — |
| 4 | CITIGROUP INC | 742 | $731.00 | 0.7% | — |
| 5 | MORGAN STANLEY | 150 | $148.00 | 0.1% | DOUBLED +503.6% |
| 6 | Vanguard Global Advisers, LLC | 102 | $100.00 | 0.1% | — |
| 7 | WELLS FARGO & COMPANY/MN | 90 | $89.00 | 0.1% | — |
| 8 | DANSKE BANK A/S | 1 | $1.00 | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| UBS Group AG | NEAR_EXIT | 31,600 | 1,192 | -96.2% | $964.00 | 2025-Q3 |
| UBS Group AG | DOUBLED | 2,957 | 31,600 | +968.7% | $24.0K | 2025-Q2 |
| MORGAN STANLEY | DOUBLED | 1,800 | 10,864 | +503.6% | $5.9K | 2024-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 23,150 | 166,600 | +619.7% | $174.9K | 2024-Q3 |
4 unique insiders with 7 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 2, 2026 | Bencich John | CHIEF FINANCIAL OFFICER | AWARD | 754,717 | — | — |
| Mar 4, 2026 | Oh Chad | CHIEF MEDICAL OFFICER | AWARD | 1,316,872 | — | — |
| Mar 4, 2026 | Wilson Alexander Blair | CLO, CSO, and Corp Secretary | AWARD | 1,316,872 | — | — |
| Mar 4, 2026 | Sy Jennifer | PRINCIPAL ACCOUNTING OFFICER | AWARD | 925,925 | — | — |
| Feb 17, 2026 | Wilson Alexander Blair | CLO, CSO, and Corp Secretary | AWARD | 862,500 | — | — |
| Feb 17, 2026 | Sy Jennifer | PRINCIPAL ACCOUNTING OFFICER | AWARD | 575,000 | — | — |
| Feb 17, 2026 | Oh Chad | CHIEF MEDICAL OFFICER | AWARD | 862,500 | — | — |
3 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 0 mixed, 2 neutral. Avg impact: 5.0/10.
NEUTRAL
8-K
5/10
AEON Biopharma reported Q1 2026 results with a net loss of $11.8M ($-0.29/share), compared to net in
May 14, 2026
NEUTRAL
DEFA14A
2/10
AEON Biopharma filed a DEFA14A notice of availability of proxy materials for its 2026 Annual Meeting
Apr 29, 2026
BEARISH
8-K
8/10
AEON Biopharma received an additional delisting notice from NYSE American due to a stockholders' def
Apr 3, 2026
Historical analyst distribution (last covering-analyst action Oct 2025): 88% buy across 8 analysts — 2 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Oct 2025. No current recommendation available.
$6.70 mean target (Oct 2025)
$5.00 Low
$8.40 High
| Metric | Value |
|---|---|
| Current Price | $0.6704 |
| Target Low | $5.00 |
| Target Mean | $6.70 |
| Target Median | $6.70 |
| Target High | $8.40 |
| # Analysts | 2 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.33 | $-0.33 | $-0.33 | 45.0% | +49.2% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
| Next Q 2026-09-30 |
$-0.27 | $-0.27 | $-0.27 | 30.8% | +50.0% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
| Current FY 2026-12-31 |
$-1.05 | $-1.05 | $-1.05 | 73.4% | +46.4% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
| Next FY 2027-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | 0.0% | — |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.330 | |
| 7d ago | $-0.650 | +0.320 |
| 30d ago | $-0.650 | +0.320 |
| 60d ago | $0.000 | -0.330 |
| 90d ago | $0.000 | -0.330 |
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Oct 8, 2025 | Aegis Capital | REITERATE | Buy | Buy |
| Oct 1, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Aug 14, 2024 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Jul 10, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 30, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 15, 2024 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| May 6, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 17, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Aug 18, 2023 | HC Wainwright & Co. | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| May 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Apr 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Mar 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Feb 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Jan 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 4, 2026
other
AEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache Society
<p align="justify">IRVINE, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biophar
May 14, 2026
fda_pdufa
PDUFA: AEON — ABP-450 in BOTOX therapeutic indications — 2026-05-14
FDA target action date 2026-05-14 for AEON (AEON Biopharma, Inc.). Drug: ABP-450. Indication: BOTOX therapeutic indications. This is the date of the f
Apr 24, 2026
other
AEON Biopharma Sets Annual Shareholder Meeting
<p align="center"><em>- Annual Shareholder Meeting to be held at 10:00 am PT on June 17, 2026 -</em></p>
Apr 3, 2026
other
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711
Apr 3, 2026
activist
AEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards
AEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards
Mar 30, 2026
earnings
AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program
AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar
Mar 9, 2026
other
AEON Biopharma Appoints John Bencich as Chief Financial Officer
AEON Biopharma Appoints John Bencich as Chief Financial Officer